Bank of New York Mellon’s AYTU BioPharma AYTU Stock Holding History

Bank of New York Mellon’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-521	Closed	-$1.97K	–	4386
2022 Q4	$1.97K	Hold	521	–	–	﹤0.01%	4460
2022 Q3	$2K	Hold	521	–	–	﹤0.01%	4548
2022 Q2	$7K	Hold	521	–	–	﹤0.01%	4566
2022 Q1	$11K	Hold	521	–	–	﹤0.01%	4637
2021 Q4	$14K	Hold	521	–	–	﹤0.01%	4604
2021 Q3	$30K	Sell	521 -275	-35%	-$20.6K	﹤0.01%	4485
2021 Q2	$80K	Sell	796 -1,546	-66%	-$181K	﹤0.01%	4252
2021 Q1	$356K	Buy	2,342 +1,599	+215%	+$254K	﹤0.01%	3843
2020 Q4	$89K	Buy	743 +346	+87%	+$63K	﹤0.01%	4088
2020 Q3	$94K	Buy	397 +6	+2%	+$1.54K	﹤0.01%	3964
2020 Q2	$111K	Buy	+391	New	+$118K	﹤0.01%	3898
2019 Q3	–	Sell	-199	Closed	-$75K	–	4212
2019 Q2	$75K	Buy	+199	New	+$75.8K	﹤0.01%	4074

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of New York Mellon's AYTU Position: Q1 2023 in Review

Bank of New York Mellon sold out of AYTU BioPharma (AYTU) in Q1 2023, closing a stake of 521 shares — an estimated $1.97K sold.

Bank of New York Mellon first reported a position in AYTU in Q2 2019 and held it in 12 quarters. The position peaked at $356K in Q1 2021. 21 funds tracked by Wall St. Rank hold AYTU as of Q1 2023.

Bank of New York Mellon reported no remaining AYTU BioPharma position as of Q1 2023 after selling out during the quarter.
Bank of New York Mellon sold 521 AYTU BioPharma shares in Q1 2023, an estimated $1.97K.
Bank of New York Mellon first reported a position in AYTU BioPharma in Q2 2019 and held it in 12 quarters.
Bank of New York Mellon's AYTU BioPharma position peaked at $356K in Q1 2021.
21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2023.

Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.